The Hippo effector YAP regulates the response of cancer cells to MAPK pathway inhibitors.

@article{Lin2016TheHE,
  title={The Hippo effector YAP regulates the response of cancer cells to MAPK pathway inhibitors.},
  author={Luping Lin and Trever G. Bivona},
  journal={Molecular & cellular oncology},
  year={2016},
  volume={3 1},
  pages={e1021441}
}
RAF- and MEK-targeted therapies are approved for patients with BRAF(V600E) melanoma and under investigation in a several other tumor types, but resistance remains a major challenge. We uncovered yes-associated protein 1 (YAP1) as a mechanism of resistance to RAF-MEK inhibition in BRAF- and RAS-mutant cancers, providing a rationale for co-targeting YAP and… CONTINUE READING